Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits atte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: You, Seng Chan, Rho, Yeunsook, Bikdeli, Behnood, Kim, Jiwoo, Siapos, Anastasios, Weaver, James, Londhe, Ajit, Cho, Jaehyeong, Park, Jimyung, Schuemie, Martijn, Suchard, Marc A., Madigan, David, Hripcsak, George, Gupta, Aakriti, Reich, Christian G., Ryan, Patrick B., Park, Rae Woong, Krumholz, Harlan M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592033/
https://ncbi.nlm.nih.gov/pubmed/33107944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.16167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados